Get the Stockscreener App
534.13
1.83%
9.61
Vertex Pharmaceuticals Inc stock is traded at $534.13, with a volume of 466.33K.
It is up +1.83% in the last 24 hours and up +3.72% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$524.52
Open:
$527.18
24h Volume:
466.33K
Relative Volume:
0.31
Market Cap:
$135.38B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
31.66
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
+4.99%
1M Performance:
+3.72%
6M Performance:
+22.04%
1Y Performance:
+25.25%
1-Day Range:
$521.29
$537.81
1-Week Range:
$497.49
$528.57
52-Week Range:
$403.16
$560.25
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
534.13 | 135.38B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
817.33 | 84.15B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
205.00 | 81.84B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.45 | 55.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
379.89 | 42.97B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-21-26 | Initiated | Leerink Partners | Outperform |
| Sep-02-26 | Resumed | Morgan Stanley | Overweight |
| May-27-26 | Resumed | Truist | Buy |
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Vertex Pharma stock at EUR 464.48 ahead of the Xetra open: biotech group - AD HOC NEWS
Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors? - Yahoo Finance
Vertex Pharma stock: Third-quarter results arrive November 2 for Vertex Pharma stock - AD HOC NEWS
Vertex appoints Daniel Brennan. Vertex Pharma stock has USD 130.4 billion value - AD HOC NEWS
Vertex Pharma stock pre-market at EUR 456.53 ahead of Xetra open - AD HOC NEWS
Vertex Appoints Daniel Brennan to its Board of Directors - BioSpace
Vertex Pharmaceuticals (VRTX) Expands Board to Eleven Members wi - GuruFocus
Why Should You Think About Vertex Differently Now? - Yahoo Finance
Form 8K Vertex Pharmaceuticals Inc For: 20 October By Investing.com - Investing.com Nigeria
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals appoints Daniel Brennan to board of directors - Investing.com
Vertex Pharmaceuticals appoints Daniel Brennan to board, joins Audit and Finance Committee - TradingView
Vertex Appoints Daniel Brennan to its Board of Directors - Business Wire
Vertex Pharma stock: BofA cuts target to USD 667 for Vertex Pharma stock - ad-hoc-news.de
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
Form 4 Vertex Pharmaceuticals Inc: Bruce I. Sachs (Director) For: 15 October - Investing.com Nigeria
BofA cuts Vertex target to USD 667 for Vertex Pharmaceuticals stock - ad-hoc-news.de
Lobbying Update: $1,100,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
Vertex Pharma stock: BofA cuts target for Vertex Pharma stock from USD 672.00 to USD 667.00 - ad-hoc-news.de
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It - The Motley Fool
Where Will CRISPR Therapeutics Stock Be in 2030? - The Motley Fool
What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders - Yahoo Finance
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. - The Motley Fool
Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Abbvie, Vertex lead $32B September biopharma M&A surge - BioWorld News
Meridian International Center Unveils Inaugural New Architects of American Influence Cohort - GlobeNewswire Inc.
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? - Zacks Investment Research
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders - AOL.com
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders - The Motley Fool
What You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings Release - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know - Zacks Investment Research
Is Vertex Stock Worth More Than Its Competitors? - Trefis
If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
RBC raises target for Vertex Pharma stock from USD 570 to USD 576 - AD HOC NEWS
RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating - www.marketscreener.com
Vertex to Announce Third Quarter 2026 Financial Results November 2nd - Business Wire
Vertex Pharmaceuticals Incorpor (VRTX) Stock forecasts - Yahoo Finance UK
Vertex Pharma stock after-hours at EUR 446.63: minus 0.62 percent versus prior close - AD HOC NEWS
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vertex Pharmaceuticals Inc Stock (VRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. |
Jul 02 '26 |
Sale |
524.99 |
1,500 |
787,485 |
45,321 |
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Tatsis Ourania | Officer |
Jul 02 '26 |
Proposed Sale |
524.99 |
1,500 |
787,485 |
0 |
| McKechnie Duncan | Officer |
Jul 02 '26 |
Proposed Sale |
519.00 |
1,541 |
799,779 |
0 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
| Liu Joy | Officer |
Jul 01 '26 |
Proposed Sale |
502.71 |
828 |
416,244 |
0 |
| Bozic Carmen | EVP and CMO |
Jun 26 '26 |
Sale |
482.50 |
596 |
287,570 |
15,337 |
| Bozic Carmen | Officer |
Jun 26 '26 |
Proposed Sale |
482.50 |
596 |
287,570 |
0 |
| Bozic Carmen | Officer |
Jun 18 '26 |
Proposed Sale |
462.17 |
1,020 |
471,413 |
0 |
| Bozic Carmen | EVP and CMO |
Jun 18 '26 |
Sale |
462.17 |
1,020 |
471,413 |
15,933 |
1.45%
16.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):